Decorre a 4 e 5 de Março na Fundação Calouste Gulbenkian, em Lisboa, o workshop subordinado ao tema RNA Therepeutics.
Os promotores, Harvard Medical School Portugal e a EURONEST, pretendem reunir especialtas de renome, tanto da área clínica como investigadores, para debater os objectivos presentes e futuros no âmbito da RNA.
A entrada é gratuita mas necessária a inscrição prévia através do email:
patrodrigues@hmsportugal.org
Programa
Thursday, 4 March 2010
FROM 15h30 - Check in
16H00 - Welcome
16H10 - 16H40 - Gert Jan Van Ommen (Leiden, The Netherlands)
Theme: Skipping around: RNA based therapy development for DMD, HD and other interesting targets
16H40 - 17H10 - Adrian Krainer (Cold Spring Harbor Laboratory, USA)
Theme: Antisense correction of SMN2 splicing in the CNS for SMA therapy
17H10 - 17H40 - Mariano Garcia-Blanco (Duke Univeristy Medical Center, USA)
Theme: Host factors of pathogenic flaviviruses: potential therapeutic targets
17H40 - 18H10 - Jamal Tazi (Institute of Molecular Genetics, Montpellier, France)
Theme: Premature aging: from splicing mechanism of the LMNA gene to validation of a therapeutic approach on HGPS mouse model
Friday, 5 March 2010
09H00 - 09H30 - Tony de Fougerolles (Alnylam Pharmaceuticals, Cambridge, USA)
Theme: Development of RNAi Therapeutics
09H30 - 10H00 - Haezel Pinheiro (Exiqon, Vedbaek, Denmark)
Theme: microRNA signatures for colon cancer & mircoRNA analysis in clinical formalin fixed tissue samples and human blood plasma samples
10H00 - 10H30 - Troels Koch (Santaris Pharma, Hoersholm, Denmark)
Theme: Locked Nucleic Acid Enables efficient silencing of coding and non-coding RNA
10H30 - 11H00 COFFEE BREAK
11H00 - 11H30 - Jörg Kaufmann (Silence Therapeutics, Berlin, Germany)
Theme: Development of the AtuPLEX for RNAi-based therapies in oncology
11H30 - 12H00 - Michael P. Czech (Program in Molecular Medicine, University of Massachusetts Medical School, USA)
Theme: RNAi-based therapeutic strategies for inflammation and metabolic disease
12H00 - 12H30 - Sarah Fredriksson (GENOVIS, Lund, Sweden)
Theme: Delivery of small RNAs in vitro and in vivo is a challenge and an interesting driver of novel technologies
12H30 - 14H00 - LUNCH
14H00 - 14H30 Michael G. Kaplitt (Neurologix, New York, USA)
Theme: AAV-Mediated RNAi Gene Therapy for Neurological Disorders
14H30 - 15H00 - Sven Klussmann (NOXXON Pharma, Berlin, Germany)
Theme: Pushing Mirror-Image RNA Oligonucleotides into Clinical Studies
15H00 - 15H30 - Ryszard Kole (AVI BioPharma, Bothell, WA, USA)
Theme: Splicing modulation by oligonucleotides. From concept to clinical trials
15H30 - 16H00 - Gerard J. McGarrity (VIRxSYS, Gaithersburg, MD, USA)
Theme: In vivo production of therapeutic proteins by spliceosome-mediated RNA trans-splicing
Ver cartaz alusivo (PDF-3.45Mb)
Para mais informação consultar site HMSP